Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a progressive clinical-stage biotechnology company committed to developing transformative therapies targeting neurodegenerative and lung diseases. The company leverages innovative drug-delivery technologies to create novel treatments aimed at improving patient outcomes.
Key to Tiziana's portfolio are two prominent compounds: Milciclib and Foralumab. Milciclib, an inhibitor of cyclin-dependent kinases, is in Phase II clinical trials for thymic carcinoma, aiming to provide new hope for patients who have exhausted chemotherapy options. Foralumab, noted for being the only fully human-engineered anti-CD3 monoclonal antibody, is in various stages of clinical development for multiple sclerosis, autoimmune, and inflammatory diseases.
In a significant advancement, Tiziana recently reported positive clinical outcomes from its Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS). Intranasal administration of Foralumab led to remarkable improvement in fatigue symptoms in 70% of patients over six months, as measured by the Modified Fatigue Impact Scale (MFIS). These results signify a groundbreaking step in addressing an unmet need in MS treatment.
The company's commitment to innovation is backed by strategic partnerships with prestigious institutions like Harvard Medical School and Brigham and Women's Hospital. Tiziana’s leadership team brings extensive experience in drug development and commercialization, ensuring a firm trajectory toward regulatory approvals and market entry.
Moreover, Tiziana’s pipeline includes potential therapies for conditions like ALS, Alzheimer's, and Crohn's Disease, underscoring its dedication to tackling a broad spectrum of debilitating conditions. The company’s forward-looking approach aims to revolutionize treatment paradigms through enhanced drug delivery systems that promise increased efficacy and reduced side effects.
With a robust clinical pipeline, strategic collaborations, and innovative technologies, Tiziana Life Sciences Ltd. remains at the forefront of biopharmaceutical research, poised to make significant strides in the field of immunomodulation therapies.
Tiziana Life Sciences has announced its transition from AIM to the Main Market of the London Stock Exchange, effective January 21, 2021. Following the last trading day on AIM on January 20, the Company’s Ordinary Shares will be admitted to the Official List and commence trading on the Main Market. Tiziana focuses on developing innovative treatments for oncology, inflammation, and infectious diseases, with ongoing Phase 2 studies for its uniquely human anti-CD3 monoclonal antibody, Foralumab, targeting conditions such as Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the appointment of Dr. Neil Graham as Chief Medical Officer. Dr. Graham has extensive experience in medicines development, having previously held roles at Regeneron and Vertex. He played a key role in the launch of blockbuster drugs like Dupixent. Tiziana's unique monoclonal antibody platform for autoimmune diseases could significantly impact the treatment landscape. The company is advancing clinical studies for Foralumab, an innovative monoclonal antibody addressing various autoimmune conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced its participation in the J.P. Morgan 39th Annual Healthcare Conference 2021. CEO Dr. Kunwar Shailubhai expressed excitement about presenting significant advancements, including topline data from a COVID-19 trial expected this month and anticipated launches of multiple Phase 2 trials in 2021. The company is exploring Foralumab, a fully human anti-CD3 monoclonal antibody, for various autoimmune diseases and aims to address IL6-induced inflammation in COVID-19 patients. For more details, visit Tiziana's website.
Tiziana Life Sciences (NASDAQ: TLSA) announced its participation in Biotech Showcase 2021, providing on-demand presentations for attendees. Dr. Kunwar Shailubhai, CEO, stated that topline data from a COVID-19 trial is expected this month, with several Phase 2 trial launches planned for 2021. With the potential application of Foralumab in various autoimmune diseases, the company aims to achieve significant milestones impacting its valuation. Biotech Showcase serves as a networking platform for life science professionals and investors, promoting innovations in drug discovery.
Tiziana Life Sciences (Nasdaq: TLSA) has completed a clinical study in Brazil on nasally administered Foralumab for COVID-19 patients. The trial showed positive anecdotal feedback from patients, highlighting rapid improvement in smell sensation, a common COVID-19 symptom. The study involved 39 patients with moderate to severe COVID-19, assessing safety and efficacy against the disease. Topline data is expected in January 2021, with implications for treating coronaviruses as well as potential applications in other diseases. This novel approach aims to enhance the immune response against COVID-19 variants.
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) announces its admission of ordinary shares to the Official List of the FCA and the Main Market of the London Stock Exchange. The prospectus for this listing was approved on December 18, 2020. Key dates include the last day of trading on AIM on January 20, 2021, with delisting and trading on the Main Market commencing on January 21, 2021, at 8:00 am. Tiziana is focused on innovative therapeutics for oncology and other diseases, including advancing clinical studies for its unique fully human anti-CD3 monoclonal antibody for various conditions.
Tiziana Life Sciences (Nasdaq: TLSA) has announced its application for a standard listing on the Official List of the FCA and trading admission on the London Stock Exchange's Main Market. The company will cancel AIM trading, effective January 21, 2021, and will not issue new shares during this transition. The prospectus is expected to be published on December 18, 2020. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases, with phase 2 studies planned for its drug, foralumab.
Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company specializing in therapeutics for oncology and infectious diseases, announced a conference call led by CEO and CSO Dr. Kunwar Shailubhai on December 2, 2020, at 4:15 p.m. ET. The call will cover the company's transition from AIM to the London Stock Exchange's Standard Segment, updates on ongoing clinical trials, and recent developments. Individuals unable to attend can access a replay until December 16, 2020. The company is known for its innovative treatments, including Milciclib and Foralumab, addressing various autoimmune diseases.
Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.
Tiziana Life Sciences (Nasdaq: TLSA) announced a collaboration with Parexel to conduct a global Phase 1b/2 trial using take-home capsules of Foralumab, the only fully human anti-CD3 monoclonal antibody, for moderate to severe Crohn's Disease.
This study will enroll 60 patients across the U.S. and Europe, aiming to evaluate safety and efficacy. The Crohn's Disease therapeutics market is projected to reach $4.7 billion by 2025, emphasizing the potential of Foralumab as a safer alternative to intravenous therapies, improving patient compliance and outcomes.
FAQ
What is the current stock price of Tiziana Life Sciences Com (TLSA)?
What is the market cap of Tiziana Life Sciences Com (TLSA)?
What is Tiziana Life Sciences Ltd. specialized in?
What are the key compounds in Tiziana's pipeline?
What recent clinical results has Tiziana announced?
Who are Tiziana Life Sciences' key partners?
What diseases are targeted by Foralumab?
What is unique about Tiziana’s drug delivery approach?
What is the status of Milciclib's clinical development?
Who leads Tiziana Life Sciences?
What is the significance of Tiziana's Expanded Access Program?
How does Tiziana Life Sciences contribute to biopharmaceutical research?
